Plain-English translation of NCT05923073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called can help children and teenagers with moderate to severe Crohn's disease. works by blocking a specific part of the immune system that causes intestinal inflammation. Researchers will measure whether the medication reduces inflammation in the gut and improves disease symptoms over 12 months.
Current treatments for Crohn's disease don't work well enough for all children, and some patients develop resistance or side effects over time. This trial is exploring whether this medication offers a better option for young patients whose disease hasn't responded well to standard therapies.
You likely qualify if…
You likely don't qualify if…
The trial lasts about one year. You'll start with a 12-week treatment phase where you'll receive the medication either through an IV infusion or an injection under your skin based on your body weight. If you respond well at 12 weeks, you'll enter a maintenance phase lasting 36 more weeks where you'll continue receiving injections on a regular schedule. Throughout the trial, you'll have regular clinic visits, blood tests, and scopes to check how well the medication is working.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States